References

1. Gegg C, Xiong F, Sitney KC. (2008) Modified Fc molecules. Patent number: US7442778 B2. Assignee: Amgen Inc.. Priority date: 24/09/2004. Publication date: 28/10/2008.

2. Gourley C. (2014) Trebananib: an alternative anti-angiogenic strategy. Lancet Oncol, 15 (8): 776-7. [PMID:24950984]

3. Marchetti C, Gasparri ML, Ruscito I, Palaia I, Perniola G, Carrone A, Farooqi AA, Pecorini F, Muzii L, Panici PB. (2015) Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386). Crit Rev Oncol Hematol, 94 (3): 302-310. [PMID:25783620]

4. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY et al.. (2014) Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol, 15 (8): 799-808. [PMID:24950985]

5. Oliner JD, Min H. (2006) Specific binding agents of human angiopoietin-2. Patent number: US7138370 B2. Assignee: Amgen Inc.. Priority date: 11/10/2001. Publication date: 21/11/2006.

6. Shimamoto G, Gegg C, Boone T, Quéva C. (2012) Peptibodies: A flexible alternative format to antibodies. MAbs, 4 (5): 586-91. [PMID:22820181]

7. Wang X, Bullock AJ, Zhang L, Wei L, Yu D, Mahagaokar K, Alsop DC, Mier JW, Atkins MB, Coxon A et al.. (2014) The role of angiopoietins as potential therapeutic targets in renal cell carcinoma. Transl Oncol, 7 (2): 188-95. [PMID:24704536]